Saving your money for next purchases
瑞博西尼(Ribociclib) 凯丽隆
Ribociclib (English: Ribociclib), brand name KISQALI, is a CDK4/6 inhibitor type breast cancer drug [1][2], developed by Astex and Novartis Pharmaceuticals [3]. Applicable subjects are: hormone receptor-positive, HER2-negative patients, and postmenopausal patients with advanced breast cancer.
Share:
Products
Our offers
Delivery – when you want and anywhere
A huge selection of best products
Health Classification
Let us work together to protect precious health
